Short Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Expands By 20.3%

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 510,800 shares, an increase of 20.3% from the March 31st total of 424,500 shares. Currently, 6.7% of the shares of the company are sold short. Based on an average daily volume of 205,600 shares, the days-to-cover ratio is presently 2.5 days.

NRx Pharmaceuticals Stock Down 27.3 %

Shares of NASDAQ:NRXP opened at $2.58 on Wednesday. The business has a 50 day moving average price of $30.47 and a 200 day moving average price of $35.28. NRx Pharmaceuticals has a twelve month low of $2.21 and a twelve month high of $12.00. The company has a market cap of $25.49 million, a price-to-earnings ratio of -0.65 and a beta of 1.02.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.50) EPS for the quarter. Analysts anticipate that NRx Pharmaceuticals will post -4 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. AdvisorShares Investments LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned about 0.75% of NRx Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.